{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:12:48Z","timestamp":1780377168781,"version":"3.54.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1097\/md.0000000000005496","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T15:19:07Z","timestamp":1481210347000},"page":"e5496","source":"Crossref","is-referenced-by-count":16,"title":["The effect of sequential therapy for postmenopausal women with osteoporosis"],"prefix":"10.1097","volume":"95","author":[{"given":"Shenghan","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houchen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-33-20210226","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R2-33-20210226","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"key":"R3-33-20210226","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"R4-33-20210226","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"R5-33-20210226","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"R6-33-20210226","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-33-20210226","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"R8-33-20210226","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R9-33-20210226","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R10-33-20210226","first-page":"w13952","article-title":"The role of teriparatide in sequential and combination therapy of osteoporosis","volume":"144","author":"Meier","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"R11-33-20210226","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00223-009-9218-x","article-title":"Treatment of osteoporosis with parathyroid hormone and teriparatide","volume":"84","author":"Pleiner-Duxneuner","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"R12-33-20210226","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clinthera.2006.02.007","article-title":"Update of current therapeutic options for the treatment of postmenopausal osteoporosis","volume":"28","author":"Epstein","year":"2006","journal-title":"Clin Ther"},{"key":"R13-33-20210226","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"R14-33-20210226","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"R15-33-20210226","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthop"},{"key":"R16-33-20210226","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2006.09.003","article-title":"Bisphosphonate-related jaw necrosis\u2014severe complication in maxillofacial surgery","volume":"33","author":"Eckert","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R17-33-20210226","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/adj.12217","article-title":"Denosumab and osteonecrosis of the jaws\u2014the pharmacology, pathogenesis and a report of two cases","volume":"59","author":"O\u2019Halloran","year":"2014","journal-title":"Aust Dent J"},{"key":"R18-33-20210226","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.108.518621","article-title":"Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease","volume":"40","author":"Mosca","year":"2009","journal-title":"Stroke"},{"key":"R19-33-20210226","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"R20-33-20210226","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis\u2014where do we go from here","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med"},{"key":"R21-33-20210226","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"R22-33-20210226","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-33-20210226","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"R24-33-20210226","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"R25-33-20210226","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA"},{"key":"R26-33-20210226","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R27-33-20210226","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R28-33-20210226","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R29-33-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R30-33-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R31-33-20210226","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"R32-33-20210226","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R33-33-20210226","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R34-33-20210226","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-33-20210226","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"R36-33-20210226","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00198-006-0157-3","article-title":"Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","journal-title":"Osteoporos Int"},{"key":"R37-33-20210226","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"R38-33-20210226","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-33-20210226","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R40-33-20210226","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"key":"R41-33-20210226","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate","volume":"24","author":"Dobnig","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R42-33-20210226","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1210\/jc.2012-1844","article-title":"Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial","volume":"97","author":"Schafer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-33-20210226","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bmb\/ldn017","article-title":"Update on the treatment of post-menopausal osteoporosis","volume":"86","author":"Cole","year":"2008","journal-title":"Br Med Bull"},{"key":"R45-33-20210226","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R46-33-20210226","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"R47-33-20210226","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-33-20210226","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"R49-33-20210226","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-33-20210226","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R51-33-20210226","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R52-33-20210226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R53-33-20210226","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"R54-33-20210226","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R55-33-20210226","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"R56-33-20210226","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R57-33-20210226","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"R58-33-20210226","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/bmj.321.7261.585","article-title":"Why we need a broad perspective on meta-analysis. It may be crucially important for patients","volume":"321","author":"Gotzsche","year":"2000","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:38:31Z","timestamp":1620959911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201612060-00033"}},"subtitle":["A PRISMA-compliant meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":57,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005496","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}